Abstract: The present invention relates to novel chromophore-containing compounds useful as sunscreen agents which have the ability to absorb both UVA and UVB wavelength radiation. These compounds comprise a specific type of UVA-absorbing chromophore covalently bonded to a specific type of UVB-absorbing chromophore. The chromophore moieties are covalently bonded together such that the electron systems of these moieties are directly coupled to thereby form a new chromophore.The present invention further relates to sunscreen compositions containing the hereinbefore described type of sunscreen agents. Furthermore, the present invention relates to methods for protecting the skin of humans or lower animals from the effects of UVA and UVB wavelength radiation. This method comprises topically applying to the skin an effective coating of a sunscreen composition of the present invention.

Abstract: Methods for building bone in a human or other animal subject, comprising administering to said subject a safe and effective amount of calcium citrate malate. The calcium citrate malate is preferably administered for at least about three months. A preferred method of the invention is for the treatment of osteoporosis. The calcium citrate malate comprises a complex or a mixture of calcium salts having a ratio of moles citrate to moles malate of from about 1:0.16 to about 1:13.5. The calcium citrate malate is preferably administered in an oral dosage form, containing pharmaceutically-acceptable carriers and excipients.

Abstract: The present invention encompasses methods of using a 5-phenyl-2-furan esters, amides and ketones and compositions thereof to prevent or limit neuronal death or degeneration in a human or lower animal. These methods comprise systemically administering to such human or other animal a safe and effective amount of a compound of the formula: ##STR1## wherein (1) X is halo or nil; and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and(2) R is R.sup.1 C(O)OH, R.sup.1 C(O)N(R.sup.3).sub.2, N(R.sup.3).sub.2, OR.sup.1 N(R.sup.3).sub.2, R.sup.1 N(R.sup.3).sub.2, N(R.sup.2)R.sup.1 N(R.sup.3).sub.2, or N(R.sup.2)N(R.sup.3).sub.2 ; whereR.sup.1 is C.sub.1 -C.sub.3 alkyl which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl;R.sup.2 is hydrogen or lower alkyl; and each R.sup.3 is, independently, hydrogen or lower alkyl; or both R.sup.

Abstract: This invention relates to devices/compositions and methods for treating diseases of the oral cavity in humans and lower animals using non-biodegradable devices/compositions which are biocompatible but not bioerodible for releasing drugs in or around a periodontol pocket or gingival sulcus.

Abstract: A process for making detergent builder agglomerates by mixing crystalline aluminosilicate or layered silicate detergent builder with selected binder in an energy-intensive mixer to form free flowing agglomerates. The binder is an anionic synthetic surfactant paste or a water-soluble polymer containing at least about 50% by weight of ethylene oxide, and optionally may contain minor amounts of ethoxylated nonionic surfactant. The agglomerates are also substantially free of amorphous alkali metal silicates if free water is present.

Abstract: Disclosed are oral compositions which are effective against calculus comprising a tripolyphosphate salt and an orthophosphate salt.

Abstract: A method of preventing epileptic seizures in a human or lower animal subject susceptible to said seizures, comprising systemically administering to said subject a safe and effective amount of a compound of the formula: ##STR1## wherein (a) X is halo or nil, and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and(b) R is R.sup.1 C(O)OH, R.sup.1 C(O)N(R.sup.2).sub.2, or R.sup.1 N(R.sup.2).sub.2 ; whereR.sup.1 is C.sub.1 -C.sub.3 alkylene which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl; andeach R.sup.2 is, independently, hydrogen or lower alkyl; orboth R.sup.2 groups are connected to form a saturated 5- or 6-membered heterocycle containing 1 or 2 heteroatoms, wherein one of which is nitrogen and the other is selected from oxygen and nitrogen and said heterocycle is unsubstituted or substituted with lower alkyl or hydroxy-substituted lower alkyl;or a pharmaceutically-acceptable salt thereof.

Abstract: A mineral supplemented candy product having improved mineral bioavailability properties and which comprises a matrix of sugar-free confectionary ingredients having distributed therein multiple discrete regions of a mineral supplement composition together with multiple discrete regions of a hardboiled candy composition incorporating an edible potentiating agent.

Abstract: Disclosed are oral compositions containing phosphocitrate to provide improved anticalculus activity.

Abstract: Disclosed are oral anesthetic pharmaceutical compositions comprising: (a) from about 0.02% to about 25% of a pharmaceutically acceptable acid salt of a .beta.-aminopropiophenone, such as dyclonine HCl; (b) from about 0.02% to about 20% of saccharin; and (c) from about 1% to about 99% of a pharmaceutically acceptable oral carrier. Also provided are methods for providing an anesthetic effect in humans or animals which comprises orally administering to said human or animal a safe and effective amount of these pharmaceutical compositions. Also provided is a novel process for the manufacture of anesthetic lozenges containing a .beta.-aminopropiophenone along with saccharin.

Abstract: The present invention relates to beta-aminoethyl-substituted phenyl compounds, especially beta-aminoethoxy-substituted phenyl compounds. The present invention also relates to pharmaceutical compositions comprising a safe and effective amount of a compound of the present invention and a pharmaceutically-acceptable carrier. The present invention further relates to methods for producing analgesia and reducing inflammation, in humans and lower animals, by administering the compounds or compositions of the present invention. In addition, the present invention relates to methods for making compounds of the present invention and intermediates useful in these synthesis methods.

Abstract: The present invention provides a dual-action tablet composition comprising:(a) an outer tablet comprising a first dose of active ingredient dispersed in a pH independent hydrophilic polymer matrix; and(b) an inner tablet comprising a second dose of active ingredient in a rapidly disintegrating excipient base.This dual-action tablet is especially efficacious for those active ingredients which have half lives of less than two hours and which experience decreased absorption efficiency in the lower gastrointestinal tract. Among the preferred dual-action tablet compositions is one wherein the active ingredient in both the inner and outer tablets is guaifenesin. Upon administration, the outer tablet provides a controlled release of the active ingredient while the inner tablet gives a second dose of active ingredient after the outer tablet has partially dissolved.

Abstract: The present invention relates to oral compositions, such as dentifrices, toothpastes and mouthwashes, which provide an anticalculus benefit. These compositions comprise a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salts, along with a pharmaceutically-acceptable carrier. The present invention also relates to a method for inhibiting or reducing the development of dental calculus by contacting the oral cavity with a safe and effective amount of an anticalculus agent which is a polyepoxysuccinic acid, or its pharmaceutically-acceptable salt.

Abstract: Compositions for the transdermal delivery of buprenorphine comprising a safe and effective amount of buprenorphine in a carrier comprising:(a) a polar solvent material selected from the group consisting of C.sub.3 -C.sub.4 diols, C.sub.3 -C.sub.6 triols, and mixtures thereof; and(b) a polar lipid material selected from the group consisting of fatty alcohol esters, fatty acid esters, and mixtures thereof;wherein said polar solvent material and said polar lipid material are present in a weight ratio of solvent material:lipid material of from about 60:40 to about 99:1. Preferably, the polar solvent material is propylene glycol, and the polar lipid material is an ester of a C.sub.8 -C.sub.12 fatty alcohol or fatty acid. Particularly preferred polar lipid materials include methyl laurate and methyl caprylate. The ratio of polar solvent material to polar lipid material is preferably from about 90:10 to about 98:2.

Abstract: A method of preventing epileptic seizures in a human or mammal subject susceptible to said seizures, comprising systemically administering to said subject a safe and effective amount of a compound of the formula: ##STR1## wherein (a) X is halo or hydrogen, and Y is a substituent selected from the group consisting of unsubstituted or halogen-substituted methyl, halo, nitro, amino, and methoxy; and(b) R is N(R.sup.3).sub.2, OR.sup.1 N(R.sup.3).sub.2, N(R.sup.2)R.sup.1 N(R.sup.3).sub.2, or N(R.sup.2)N(R.sup.3).sub.2 ; whereR.sup.1 is C.sub.1 -C.sub.3 alkylene which is unsubstituted or substituted with C.sub.1 -C.sub.2 alkyl;R.sup.2 is hydrogen or lower alkyl; andeach R.sup.3 is, independently, hydrogen or lower alkyl; or both R.sup.

Abstract: The present invention relates to oral hygiene compositions having improved anticalculus activity containing a mixture of a sodium and potassium pyrophosphate salt and a polyacrylic acid or salt thereof or copolymers of acrylic acid and another monomer or mixtures thereof and an effective amount of a water soluble fluoride salt in a pharmaceutically acceptable carrier to provide enhanced anticalculus benefits.

Abstract: Disclosed are facial cleansing compositions in the form of an oil-in-water emulsion which contain specific surfactants with an HLB above about 10 in combination with specific polyalphaolefins and specific carboxylic copolymers which provide improved cleansing efficacy as well as improved rinsability and improved skin feel (such as a nongreasy feeling).

Abstract: An oral hygiene compositions possessing antiplaque and antigingivitis properties containing stannous fluoride stabilized with stannous gluconate in an orally acceptable carrier at pH of from about 3.0% about 4.79 and said composition is substantially free of a calcium ion source.

Abstract: Disclosed are oral compositions containing particular pyrophosphate salts which provide an anticalculus benefit.

Abstract: Disclosed are oral pharmaceutical preparations which comprise a pharmacologically active drug bound to small particles of an ion-exchange resin to provide a drug-resin complex having a drug content above a specified value. The drug-resin complex is subsequently coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug under conditions encountered in the gastrointestinal tract.